Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Rhythm Pharmaceuticals
Deal Size : $211.0 million
Deal Type : Acquisition
Details : Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity
Product Name : Imcivree
Product Type : Peptide
Upfront Cash : $5.0 million
February 27, 2023
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Rhythm Pharmaceuticals
Deal Size : $211.0 million
Deal Type : Acquisition
Reset All
